Last edition
News about "TCE program"
Antengene Licenses ATG-106 to K2 Therapeutics in Strategic Deal
Antengene has granted K2 Therapeutics exclusive global rights to develop and commercialise ATG-106 outside Greater China under a strategic licensing agreement that also includes an option for an undisclosed bispecific T-Cell Engager (TCE).
TCE Program | 24/06/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members